The primary endpoints are Proportion of Participants in the microbiological Intent-to-treat (micro-ITT) Population demonstrating Clinical Cure and Microbiologic Success at the End of Intravenous (EOI) Visit [Time Frame: EOI visit (within 1 day of the completion of intravenous study drug treatment) ] & Proportion of Participants in the micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit [ Time Frame: TOC visit (14–17 days after randomization) ]. With secondary endpoints(outcomes) testing Proportion of Participants in the microbiological Modified Intent-To-Treat (micro-MITT) Population and the Microbiologically Evaluable (ME) Population Demonstrating Microbiologic Success at the TOC Visit [ Time Frame: TOC visit (14–17 days after randomization) ]

Commercial information
Eravacycline is under development by Tetraphase Pharmaceuticals Inc. It is marketed under trade name Xerava in United States. References
External links
"Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI: Eravacycline Did Not Achieve Primary Endpoint in Pivotal Portion of cUTI Trial"
Tetraphase pipeline
Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development
If acute hepatic artery thrombosis occurs after liver transplantation, then retransplantation with a new liver may be necessary.However, chronic hepatic artery thrombosis may not require therapy, as the gradual development of additional blood vessels (collateral circulation) may be adequate for the metabolic needs of the liver. Prognosis
The development of hepatic artery thrombosis soon after liver transplantation is associated with higher risk of death (mortality) and transplanted liver failure (graft loss). Epidemiology
Hepatic artery thrombosis is the most common complication that occurs after liver transplantation. Hepatic artery thrombosis may also occur after other surgeries. Hepatic artery thrombosis and primary non-function are the two most common reason that a transplanted liver fails to work (graft failure). Among people who receive liver transplants, smoking tobacco increases the risk of hepatic artery thrombosis. == References ==